Ophthotech Corp (OPHT)

52.90
0.47 0.88
NASDAQ : Health Care
Prev Close 53.37
Open 53.33
Day Low/High 52.62 / 53.81
52 Wk Low/High 35.72 / 80.00
Volume 46.86K
Avg Volume 494.90K
Exchange NASDAQ
Shares Outstanding 35.59M
Market Cap 1.89B
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ophthotech Announces Election Of Ian F. Smith, Vertex Executive Vice President And Chief Financial Officer, To Its Board Of Directors

Ophthotech Announces Election Of Ian F. Smith, Vertex Executive Vice President And Chief Financial Officer, To Its Board Of Directors

Ophthotech Corporation (Nasdaq:OPHT) today announced the election of Ian F.

Short Interest Moves 17% Higher For OPHT

Short Interest Moves 17% Higher For OPHT

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 434,231 share increase in total short interest for Ophthotech Corp , to 2,977,494, an increase of 17.07% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ophthotech Corporation To Report Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016

Ophthotech Corporation To Report Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016

Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2016 financial results on Wednesday, August 3, 2016.

These 4 Stocks Are Poised for Breakout Profits

These 4 Stocks Are Poised for Breakout Profits

Positive momentum and money flow set the stage for higher prices in these four stocks.

Ophthotech Completes Patient Recruitment In Phase 3 Trial Of Fovista® Anti-PDGF Therapy In Combination With Eylea® Or Avastin® In Wet Age-Related Macular Degeneration

Ophthotech Completes Patient Recruitment In Phase 3 Trial Of Fovista® Anti-PDGF Therapy In Combination With Eylea® Or Avastin® In Wet Age-Related Macular Degeneration

Ophthotech Corporation (Nasdaq: OPHT) today announced the completion of patient recruitment in its Phase 3 trial of Fovista ® (pegpleranib), anti-PDGF therapy, in combination with Eylea ® (aflibercept) or...

Insider Trading Alert - OPHT, MMS And MLNX Traded By Insiders

Insider Trading Alert - OPHT, MMS And MLNX Traded By Insiders

Stocks with insider trader activity include OPHT, MMS and MLNX

Stock To Watch: Ophthotech (OPHT) In Perilous Reversal

Stock To Watch: Ophthotech (OPHT) In Perilous Reversal

Trade-Ideas LLC identified Ophthotech (OPHT) as a "perilous reversal" (up big yesterday but down big today) candidate

Analysts' Actions -- Box, Bristol-Myers, Newmont Mining, Exxon Mobil and More

Analysts' Actions -- Box, Bristol-Myers, Newmont Mining, Exxon Mobil and More

Here are Thursday's top research calls, including an upgrade for Bristol-Myers Squibb, and downgrades for Box, Newmont Mining and Exxon Mobil.

Ophthotech Corporation To Present At The Goldman Sachs 37th Annual Global Healthcare Conference

Ophthotech Corporation To Present At The Goldman Sachs 37th Annual Global Healthcare Conference

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.

Ophthotech Reports First Quarter 2016 Financial And Operating Results

Ophthotech Reports First Quarter 2016 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Company's business and product development programs.

Carmen A. Puliafito, MD, MBA, Former Dean Of Keck School Of Medicine Of The University Of Southern California, Joins Ophthotech As Chief Of Strategic Development

Carmen A. Puliafito, MD, MBA, Former Dean Of Keck School Of Medicine Of The University Of Southern California, Joins Ophthotech As Chief Of Strategic Development

Ophthotech Corporation (NASDAQ: OPHT) announced today the appointment of Carmen A.

Ophthotech Corporation To Report First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 4, 2016

Ophthotech Corporation To Report First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 4, 2016

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2016 financial results on Wednesday, May 4, 2016.

Trade-Ideas: Ophthotech (OPHT) Is Today's

Trade-Ideas: Ophthotech (OPHT) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Ophthotech (OPHT) as a "perilous reversal" (up big yesterday but down big today) candidate

Ophthotech (OPHT) Highlighted As Weak On High Volume

Ophthotech (OPHT) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Ophthotech (OPHT) as a weak on high relative volume candidate

Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock

Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Ophthotech (OPHT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Perilous Reversal Stock: Ophthotech (OPHT)

Perilous Reversal Stock: Ophthotech (OPHT)

Trade-Ideas LLC identified Ophthotech (OPHT) as a "perilous reversal" (up big yesterday but down big today) candidate

Ophthotech Corporation To Present At Barclays Global Healthcare Conference 2016

Ophthotech Corporation To Present At Barclays Global Healthcare Conference 2016

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.

Ophthotech (OPHT) Showing Signs Of A Dead Cat Bounce Today

Ophthotech (OPHT) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Ophthotech (OPHT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Ophthotech Reports Fourth Quarter And Full Year 2015 Financial And Operating Results

Ophthotech Reports Fourth Quarter And Full Year 2015 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on the Company's business and product development programs.

Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock

Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Ophthotech (OPHT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Ophthotech Corporation To Present At RBC Capital Markets Healthcare Conference

Ophthotech Corporation To Present At RBC Capital Markets Healthcare Conference

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.

Ophthotech Corporation To Report Fourth Quarter 2015 Financial Results And Host Conference Call On Wednesday, February 24, 2016

Ophthotech Corporation To Report Fourth Quarter 2015 Financial Results And Host Conference Call On Wednesday, February 24, 2016

Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and year ended December 31, 2015 financial results on Wednesday, February 24, 2016.

Insider Trading Alert - TLMR, TWC And OPHT Traded By Insiders

Insider Trading Alert - TLMR, TWC And OPHT Traded By Insiders

Stocks with insider trader activity include TLMR, TWC and OPHT

Ophthotech Corporation To Present At The LEERINK Partners 5th Annual Global Healthcare Conference

Ophthotech Corporation To Present At The LEERINK Partners 5th Annual Global Healthcare Conference

Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.

Ophthotech Announces First Patient Dosed In Zimura® Phase 2/3 Study To Evaluate Treatment In Patients With Geographic Atrophy, An Advanced Form Of Dry Age-Related Macular Degeneration

Ophthotech Announces First Patient Dosed In Zimura® Phase 2/3 Study To Evaluate Treatment In Patients With Geographic Atrophy, An Advanced Form Of Dry Age-Related Macular Degeneration

Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura ® (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with...

Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock

Ophthotech (OPHT) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Ophthotech (OPHT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Ophthotech Announces Appointment Of David E. Redlick To Its Board Of Directors

Ophthotech Announces Appointment Of David E. Redlick To Its Board Of Directors

Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E.

Glenn P. Sblendorio To Join Ophthotech As Executive Vice President, Chief Operating Officer And Chief Financial Officer

Glenn P. Sblendorio To Join Ophthotech As Executive Vice President, Chief Operating Officer And Chief Financial Officer

Ophthotech Corporation (NASDAQ: OPHT) today announced that Glenn P.